what is glp-1 agonist PDB-101: Molecule of the Month: Receptor Agonists Clinical Focus on GLP-1 Agonists

Boubia B, Poupardin O, Barth M et al (2018) Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) alpha/gamma/delta Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

The PREDIMED trial provided participants with approximately 50 ml per day (about one litre per week for household use)

Mechanisms of amylin/leptin synergy in rodent models

& Khan, N

If you are curious about Saxenda or any other weight loss drug, talk to your healthcare provider about whether or not these treatment options are right for you

Furthermore, alongside the increasing prevalence of related cardiometabolic diseases such as diabetes, obesity and chronic kidney disease (CKD), the number of people with HF has increased to around 64 million globally, amongst whom most are also living with type 2 diabetes or obesity (Groenewegen et al., 2020)